doi: 10.1161/01.HYP.0000019128.94483.3A
(Hypertension. 2002;39:1053.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
ADD1 460W Allele Associated With Cardiovascular Disease in Hypertensive Individuals
From the Human Genetics Center, University of Texas–Houston Health Science Center (A.C.M., M.S.B., E.B.), Houston; Division of Epidemiology, School of Public Health, University of Minnesota (A.R.F.), Minneapolis; and Institute of Molecular Medicine (E.B.), Houston, Tex.
Correspondence to Eric Boerwinkle, PhD, Human Genetics Center, University of Texas–Houston Health Science Center, 1200 Herman Pressler; Suite 453E, Houston, TX 77030. E-mail Eric.Boerwinkle@ uth.tmc.edu
Abstract— High blood pressure is a predictor of cardiovascular disease. Hence, genes contributing to essential hypertension may play a role in the etiology of cardiovascular disease. For this reason, we examined the association between the 
-adducin (ADD1) G460W and G-protein ß3 subunit (GNB3) 825C>T polymorphisms and the prevalence of peripheral arterial disease (PAD) and incidence of coronary heart disease (CHD) in non-Hispanic whites from the Atherosclerosis Risk in Communities (ARIC) Study. PAD prevalence was defined by an ankle-brachial index, ie, the ratio of ankle systolic blood pressure to brachial artery systolic blood pressure, of 
0.90 for men and 0.85 for women. CHD incidence was determined by following the ARIC cohort for a median of 5.3 years for potential coronary events. Stratified random samples of the ARIC cohort (n=703 and n=684) were used, respectively, as the comparison groups for the PAD (n=144) and incident CHD (n=408) cases. The GNB3 825T allele and the ADD1 460W allele were not significantly associated with prevalence of PAD or incidence of CHD. However, a test of the interaction between hypertension status and the ADD1 G460W polymorphism indicated that further evaluation of the ADD1 polymorphism in only hypertensive individuals was warranted. The ADD1 460W allele was significantly associated with PAD (odds ratio [OR]: 2.61, 95% CI, 1.27–5.37, P=0.01) and CHD (hazard rate ratio [HRR]: 2.30, 95% CI, 1.20–4.42, P=0.01) in hypertensive individuals after adjustment for multiple cardiovascular disease risk factors. An interaction with hypertension in the association between the ADD1 G460W polymorphism and cardiovascular disease merits further testing in additional populations.
Key Words: genetics • risk factors • polymorphism • hypertension, essential • cardiovascular diseases
This article has been cited by other articles:
 |
|
 |
|
  E. Zintzaras and N. Zdoukopoulos A Field Synopsis and Meta-Analysis of Genetic Association Studies in Peripheral Arterial Disease: The CUMAGAS-PAD Database Am. J. Epidemiol., July 1, 2009; 170(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Manunta, G. Lavery, C. Lanzani, P. S. Braund, M. Simonini, C. Bodycote, L. Zagato, S. Delli Carpini, C. Tantardini, E. Brioni, et al. Physiological Interaction Between {alpha}-Adducin and WNK1-NEDD4L Pathways on Sodium-Related Blood Pressure Regulation Hypertension, August 1, 2008; 52(2): 366 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. van der Net, J. van Etten, M. Yazdanpanah, G. M. Dallinga-Thie, J. J.P. Kastelein, J. C. Defesche, R. P. Koopmans, E. W. Steyerberg, and E. J.G. Sijbrands Gene-load score of the renin-angiotensin-aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia Eur. Heart J., June 1, 2008; 29(11): 1370 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cappuzzello, R. Melchionna, A. Mangoni, G. Tripodi, P. Ferrari, L. Torielli, D. Arcelli, M. Helmer-Citterich, G. Bianchi, M. C. Capogrossi, et al. Role of rat {alpha} adducin in angiogenesis: Null effect of the F316Y polymorphism Cardiovasc Res, August 1, 2007; 75(3): 608 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Morrison, L. A. Bare, L. E. Chambless, S. G. Ellis, M. Malloy, J. P. Kane, J. S. Pankow, J. J. Devlin, J. T. Willerson, and E. Boerwinkle Prediction of Coronary Heart Disease Risk using a Genetic Risk Score: The Atherosclerosis Risk in Communities Study Am. J. Epidemiol., July 1, 2007; 166(1): 28 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, L. Zagato, T. Kuznetsova, G. Tripodi, G. Zerbini, T. Richart, L. Thijs, P. Manunta, J.-G. Wang, G. Bianchi, et al. Angiotensin-Converting Enzyme I/D and {alpha}-Adducin Gly460Trp Polymorphisms: From Angiotensin-Converting Enzyme Activity to Cardiovascular Outcome Hypertension, June 1, 2007; 49(6): 1291 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Rana, P. A. Insel, S. H. Payne, K. Abel, E. Beutler, M. G. Ziegler, N. J. Schork, and D. T. O'Connor Population-Based Sample Reveals Gene-Gender Interactions in Blood Pressure in White Americans Hypertension, January 1, 2007; 49(1): 96 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. E. van Rijn, M. J. Bos, M. Yazdanpanah, A. Isaacs, A. Arias-Vasquez, P. J. Koudstaal, A. Hofman, J. C. Witteman, C. M. van Duijn, and M. M. B. Breteler {alpha}-Adducin Polymorphism, Atherosclerosis, and Cardiovascular and Cerebrovascular Risk Stroke, December 1, 2006; 37(12): 2930 - 2934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yazdanpanah, F. A. Sayed-Tabatabaei, A. Hofman, Y. S. Aulchenko, B. A. Oostra, B. H.C. Stricker, H. A.P. Pols, S. W.J. Lamberts, J. C.M. Witteman, J. A.M.J.L. Janssen, et al. The {alpha}-Adducin Gene Is Associated With Macrovascular Complications and Mortality in Patients With Type 2 Diabetes. Diabetes, October 1, 2006; 55(10): 2922 - 2927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Assmann Dyslipidaemia and global cardiovascular risk: clinical issues Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F40 - F46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Manunta and G. Bianchi Pharmacogenomics and Pharmacogenetics of Hypertension: Update and Perspectives--The Adducin Paradigm J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S30 - S35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bianchi Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1536 - R1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, L. Thijs, T. Kuznetsova, L. Zagato, H. Struijker-Boudier, G. Bianchi, and J. A. Staessen Cardiovascular Risk in Relation to {alpha}-Adducin Gly460Trp Polymorphism and Systolic Pressure: A Prospective Population Study Hypertension, September 1, 2005; 46(3): 527 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bianchi, P. Ferrari, and J. A. Staessen Adducin Polymorphism: Detection and Impact on Hypertension and Related Disorders Hypertension, March 1, 2005; 45(3): 331 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Conway, R. Martin, A.-J. McKnight, D. A. Savage, H. R. Brady, and A. P. Maxwell Role of {alpha}-adducin DNA polymorphisms in the genetic predisposition to diabetic nephropathy Nephrol. Dial. Transplant., August 1, 2004; 19(8): 2019 - 2024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Gibbons, C. C. Liew, M. O. Goodarzi, J. I. Rotter, W. A. Hsueh, H. M. Siragy, R. Pratt, and V. J. Dzau Genetic Markers: Progress and Potential for Cardiovascular Disease Circulation, June 29, 2004; 109(25_suppl_1): IV-47 - IV-58. [Full Text] [PDF]
|
|
|
|
|
|
F. C. Luft Geneticism of Essential Hypertension Hypertension, June 1, 2004; 43(6): 1155 - 1159. [Full Text] [PDF]
|
|
|
|
|
|
B. Kaynak, A. von Heydebreck, S. Mebus, D. Seelow, S. Hennig, J. Vogel, H.-P. Sperling, R. Pregla, V. Alexi-Meskishvili, R. Hetzer, et al. Genome-Wide Array Analysis of Normal and Malformed Human Hearts Circulation, May 20, 2003; 107(19): 2467 - 2474. [Abstract] [Full Text] [PDF]
|
|